PDCD1 and melanoma: In 2014, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab and pembrolizumab for advanced melanoma treatment, establishing these agents as the first programmed death 1 (PD-1) inhibitors to receive regulatory authorization [1].